2. Search Result
Search Result
Results for "

acute bacterial skin

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14865
    Omadacycline
    Maximum Cited Publications
    32 Publications Verification

    PTK 0796; Amadacycline

    		 Bacterial Antibiotic Infection
    Omadacycline (PTK 0796), a first-in-class orally active aminomethylcycline antibacterial, is a member of the tetracycline class of antibiotics. Omadacycline acts through the inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline possesses broad-spectrum antibacterial activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, as well as atypical bacteria. Omadacycline can be used for the research of acute bacterial skin and skin-structure infections, community-acquired pneumonia, and urinary tract infections .
    Omadacycline
  • HY-14865B
    Omadacycline tosylate
    Maximum Cited Publications
    32 Publications Verification

    PTK 0796 tosylate; Amadacycline tosylate

    		 Bacterial Antibiotic Infection
    Omadacycline (PTK 0796) tosylate, a first-in-class orally active aminomethylcycline antibacterial, is a member of the tetracycline class of antibiotics. Omadacycline tosylate acts through the inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline tosylate possesses broad-spectrum antibacterial activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, as well as atypical bacteria. Omadacycline tosylate can be used for the research of acute bacterial skin and skin-structure infections, community-acquired pneumonia, and urinary tract infections .
    Omadacycline tosylate
  • HY-16764
    Avarofloxacin

    JNJ-Q2

    		 Bacterial Antibiotic Infection Inflammation/Immunology
    Avarofloxacin (JNJ-Q2) is a broad-spectrum fluoroquinolone antibacterial agent being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia with oral activity. Avarofloxacin (JNJ-Q2) is an aminoethylidenylpiperidine fluoroquinolone that demonstrates antibacterial effect against numerous Gram-positive bacteria with a mean 0.12 mg/L MIC90 value. Avarofloxacin (JNJ-Q2) has potential for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections .
    Avarofloxacin
  • HY-14865C
    Omadacycline hydrochloride
    Maximum Cited Publications
    32 Publications Verification

    PTK0796 hydrochloride; Amadacycline hydrochloride

    		 Bacterial Antibiotic Infection
    Omadacycline (PTK 0796) hydrochloride, a first-in-class orally active aminomethylcycline antibacterial, is a member of the tetracycline class of antibiotics. Omadacycline hydrochloride acts through the inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline hydrochloride possesses broad-spectrum antibacterial activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, as well as atypical bacteria. Omadacycline hydrochloride can be used for the research of acute bacterial skin and skin-structure infections, community-acquired pneumonia, and urinary tract infections .
    Omadacycline hydrochloride
  • HY-N7101
    Cefpodoxime Proxetil

    U-76,252; CS-807

    		 Bacterial Antibiotic Penicillin-binding protein (PBP) Infection
    Cefpodoxime Proxetil is an orally active broad spectrum third-generation cephalosporin with potent antibacterial activity against both Gram-positive and Gram-negative bacteria including staphylococci, streptococci, Haemophilus influenzae, Neisseria gonorrhoeae, Escherichia coli, Klebsiella pnuemoniae, Citrobacter spp, and Proteus spp. Cefpodoxime Proxetil binds to penicillin binding proteins (PBPs), which inhibits peptidoglycan synthesis, finally results in interfering bacterial cell wall biosynthesis. Cefpodoxime Proxetil can be used against skin structure infections, acute otitis media, pharyngitis, tonsillitis, upper respiratory tract infection, urinary tract infections and sexually transmitted diseases .
    Cefpodoxime Proxetil
  • HY-12480
    Lanopepden

    GSK 1322322

    		 Bacterial Infection
    Lanopepden (GSK 1322322) is a peptidyl peptidase (PDF) inhibitor. Lanopepden inhibits PDF activity, preventing bacterial protein synthesis, thereby exerting antibacterial activity. Lanopepden is primarily effective against Gram-positive bacteria. Lanopepden is used in the study of acute bacterial skin and skin structure infections .
    Lanopepden
  • HY-139554
    Zifanocycline

    KBP-7072

    		 Antibiotic Bacterial Infection
    Zifanocycline (KBP-7072) is a semisynthetic third-generation aminomethylcycline antibiotic that inhibits the normal function of the bacterial ribosome. Zifanocycline exhibits a broad spectrum of in vitro antibacterial activity against Gram-positive and Gram-negative bacteria, including many multidrug-resistant pathogens. Zifanocycline is available in both oral and injectable formulations. Zifanocycline can be used for the research of acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, and complicated intra-abdominal infections .
    Zifanocycline
  • HY-113640
    BC-7013

    		Bacterial Infection
    BC-7013 is a novel semi-synthetic pleuromutilin derivative. BC-7013 has excellent activity against Gram-positive pathogenic bacteria. BC-7013 exhibits potent antibacterial properties against both Staphylococcus, Streptococcus and penicillin-resistant Streptococcus pneumoniae. BC-7013 has activity against Gram-positive pathogenic bacteria, BC-7013 is useful in the research of acute bacterial skin and skin structure infection (ABSSSI) .
    BC-7013
  • HY-14865BR
    Omadacycline tosylate (Standard)

    PTK 0796 tosylate (Standard); Amadacycline tosylate (Standard)

    		 Reference Standards Bacterial Antibiotic Infection
    Omadacycline (tosylate) (Standard) is the analytical standard of Omadacycline (tosylate). This product is intended for research and analytical applications. Omadacycline (PTK 0796) tosylate, a first-in-class orally active aminomethylcycline antibacterial, is a member of the tetracycline class of antibiotics. Omadacycline tosylate acts through the inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline tosylate possesses broad-spectrum antibacterial activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, as well as atypical bacteria. Omadacycline tosylate can be used for the research of acute bacterial skin and skin-structure infections, community-acquired pneumonia, and urinary tract infections .
    Omadacycline tosylate (Standard)
  • HY-14865A
    Omadacycline mesylate

    PTK 0796 mesylate; Amadacycline mesylate

    		 Bacterial Antibiotic Infection
    Omadacycline (PTK 0796) mesylate, a first-in-class orally active aminomethylcycline antibacterial, is a member of the tetracycline class of antibiotics. Omadacycline mesylate acts through the inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline mesylate possesses broad-spectrum antibacterial activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, as well as atypical bacteria. Omadacycline mesylate can be used for the research of acute bacterial skin and skin-structure infections, community-acquired pneumonia, and urinary tract infections .
    Omadacycline mesylate
  • HY-14865CR
    Omadacycline hydrochloride (Standard)

    PTK0796 hydrochloride (Standard); Amadacycline hydrochloride (Standard)

    		 Reference Standards Bacterial Antibiotic Infection
    Omadacycline (hydrochloride) (Standard) is the analytical standard of Omadacycline (hydrochloride). This product is intended for research and analytical applications. Omadacycline (PTK 0796) hydrochloride, a first-in-class orally active aminomethylcycline antibacterial, is a member of the tetracycline class of antibiotics. Omadacycline hydrochloride acts through the inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline hydrochloride possesses broad-spectrum antibacterial activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, as well as atypical bacteria. Omadacycline hydrochloride can be used for the research of acute bacterial skin and skin-structure infections, community-acquired pneumonia, and urinary tract infections[1][2][3][4].
    Omadacycline hydrochloride (Standard)
  • HY-14865R
    Omadacycline (Standard)

    PTK 0796 (Standard); Amadacycline (Standard)

    		 Reference Standards Bacterial Antibiotic Infection
    Omadacycline (Standard) is the analytical standard of Omadacycline. This product is intended for research and analytical applications. Omadacycline (PTK 0796), a first-in-class orally active aminomethylcycline antibacterial, is a member of the tetracycline class of antibiotics. Omadacycline acts through the inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline possesses broad-spectrum antibacterial activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, as well as atypical bacteria. Omadacycline can be used for the research of acute bacterial skin and skin-structure infections, community-acquired pneumonia, and urinary tract infections .
    Omadacycline (Standard)
  • HY-116598
    Lanopepden mesylate

    GSK 1322322 mesylate

    		 Bacterial Infection
    Lanopepden mesylate (GSK 1322322 mesylate) is a peptide deformase (PDF) inhibitor. Lanopepden mesylate has antibacterial activity by inhibiting the activity of PDF, preventing the correct synthesis of bacterial proteins. Lanopepden mesylate mainly targets Gram-positive bacteria. Lanopepden mesylate can be used in the study of acute bacterial skin and skin structural infections .
    Lanopepden mesylate
  • HY-139554A
    Zifanocycline TFA
    1 Publications Verification

    KBP-7072 TFA

    		 Bacterial Infection
    Zifanocycline (KBP-7072) TFA is an orally active, semi-synthetic aminomethylcycline antibiotic that inhibits the normal function of bacterial ribosomes. Zifanocycline TFA has broad spectrum in vitro antimicrobial activity against Gram-positive and Gram-negative bacteria, including many multidrug-resistant pathogens. Zifanocycline TFA is indicated for the study of acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, and complicated intra-abdominal infections .
    Zifanocycline TFA
  • HY-16764A
    Acorafloxacin hydrochloride

    JNJ-Q2 hydrochloride

    		 Bacterial Infection Inflammation/Immunology
    Acorafloxacin hydrochloride (JNJ-Q2 hydrochloride) is a broad-spectrum fluoroquinolone anti-bacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia . Acorafloxacin hydrochloride is an aminoethylidenylpiperidine fluoroquinolone that demonstrates antibacterial effect against numerous Gram-positive bacteria with a mean 0.12 mg/L MIC90 value . Acorafloxacin hydrochloride has potential for study of methicillin-resistant Staphylococcus aureus (MRSA) infections .
    Acorafloxacin hydrochloride
  • HY-139554AR
    Zifanocycline TFA (Standard)

    KBP-7072 TFA (Standard)

    		 Bacterial Antibiotic Reference Standards Infection
    Zifanocycline (TFA) (Standard) is the analytical standard of Zifanocycline (TFA). This product is intended for research and analytical applications. Zifanocycline (KBP-7072) TFA is an orally active, semi-synthetic aminomethylcycline antibiotic that inhibits the normal function of bacterial ribosomes. Zifanocycline TFA has broad spectrum in vitro antimicrobial activity against Gram-positive and Gram-negative bacteria, including many multidrug-resistant pathogens. Zifanocycline TFA is indicated for the study of acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, and complicated intra-abdominal infections[1][2].
    Zifanocycline TFA (Standard)
  • HY-17626A
    Alalevonadifloxacin mesylate

    WCK-2349 mesylate

    		 Antibiotic Bacterial Infection
    Alalevonadifloxacin (WCK-2349) mesylate is an orally active antibiotic targeting Gram-positive and Gram-negative bacteria. Alalevonadifloxacin mesylate is promising for research of acute bacterial skin and skin structure infections and hospital-acquired pneumonia caused by MRSA and other pathogens .
    Alalevonadifloxacin mesylate
  • HY-N7101R
    Cefpodoxime Proxetil (Standard)

    U-76,252 (Standard); CS-807 (Standard)

    		 Reference Standards Bacterial Antibiotic Penicillin-binding protein (PBP) Infection
    Cefpodoxime Proxetil (Standard) is the analytical standard of Cefpodoxime Proxetil. This product is intended for research and analytical applications. Cefpodoxime Proxetil is an orally active broad spectrum third-generation cephalosporin with potent antibacterial activity against both Gram-positive and Gram-negative bacteria including staphylococci, streptococci, Haemophilus influenzae, Neisseria gonorrhoeae, Escherichia coli, Klebsiella pnuemoniae, Citrobacter spp, and Proteus spp. Cefpodoxime Proxetil binds to penicillin binding proteins (PBPs), which inhibits peptidoglycan synthesis, finally results in interfering bacterial cell wall biosynthesis. Cefpodoxime Proxetil can be used against skin structure infections, acute otitis media, pharyngitis, tonsillitis, upper respiratory tract infection, urinary tract infections and sexually transmitted diseases .
    Cefpodoxime Proxetil (Standard)
  • HY-N7101S
    Cefpodoxime proxetil-d7

    U-76-d7,252-d7; CS-807-d7

    		 Isotope-Labeled Compounds Bacterial Antibiotic Penicillin-binding protein (PBP) Infection
    Cefpodoxime proxetil-d7 (U-76-d7,252-d7; CS-807-d7) is the deuterium labeled Cefpodoxime Proxetil (HY-N7101). Cefpodoxime Proxetil is an orally active broad spectrum third-generation cephalosporin with potent antibacterial activity against both Gram-positive and Gram-negative bacteria including staphylococci, streptococci, Haemophilus influenzae, Neisseria gonorrhoeae, Escherichia coli, Klebsiella pnuemoniae, Citrobacter spp, and Proteus spp. Cefpodoxime Proxetil binds to penicillin binding proteins (PBPs), which inhibits peptidoglycan synthesis, finally results in interfering bacterial cell wall biosynthesis. Cefpodoxime Proxetil can be used against skin structure infections, acute otitis media, pharyngitis, tonsillitis, upper respiratory tract infection, urinary tract infections and sexually transmitted diseases .
    Cefpodoxime proxetil-d7

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: